The revolution of personalized medicine in oncology
The Genomic testing in metastatic breast cancer, These are advanced studies that analyze tumor DNA to identify specific mutations. These tests help doctors select personalized treatments, targeting the genetic alterations that drive cancer growth. These tests have transformed how this disease is diagnosed and treated. In recent years, next-generation sequencing (NGS), an advanced technology that allows for rapid and detailed DNA analysis, has made it possible to identify specific genetic mutations in tumors, leading to the development of targeted therapies that are more effective and have fewer side effects.
Why are genomic tests important in metastatic breast cancer?
He metastatic breast cancer (mBC) remains a challenge for medicine. Although conventional treatments such as chemotherapy and hormone therapy exist, not all patients respond in the same way. A recent study published in the International Journal of Molecular Sciences assessed the impact of the Genomic testing in metastatic breast cancer in the selection of personalized treatments.
Key findings from the study:
- They were analyzed 101 patients with metastatic breast cancer in the Modena Cancer Center.
- NGS tests were used to identify mutations in the tumor.
- 60.4% of the patients presented pathogenic mutations.
- 46 patients (75%) They had at least one actionable mutation, that is, one that could be treated with targeted therapies.
- 9% of the patients They received treatment based on the results of the genomic test.
These findings confirm that the Genomic testing in metastatic breast cancer They can play a key role in personalizing cancer treatment, allowing doctors to tailor therapies to the specific needs of each patient.
Main mutations detected and their impact on treatment
The study revealed that the most frequent mutations in metastatic breast tumors were:
- PIK3CA (47%): Associated with a better response to the PI3K inhibitor, alpelisib.
- FGFR (19%)It can be treated with FGFR inhibitors in clinical trials.
- ERBB2 (12%)Related to the effectiveness of therapies targeting HER2.
Patients who received targeted therapies based on their genetic profile showed an improvement in disease progression. Although the use of these tests in daily practice is still under discussion, these data support their growing utility in modern oncology.
Benefits of genomic testing in oncology
- Selection of personalized treatmentsThey allow the identification of specific therapies for each patient, increasing the effectiveness of the treatment and reducing unnecessary adverse effects.
- Detection of actionable mutationsThey help to find mutations that can be treated with drugs already approved or in clinical trials.
- Disease monitoringIn some cases, genomic testing can be performed periodically to detect the emergence of new mutations that may influence the response to treatment.
Challenges and future of genomic testing in metastatic breast cancer
Despite its potential, the implementation of NGS in clinical practice faces some challenges:
- Cost and accessibilityAlthough its price has decreased, it still represents a significant investment for some patients and health systems.
- Interpretation of the resultsNot all mutations found have an available treatment, which can create uncertainty in clinical management.
- Evidence from clinical trialsMore studies are needed to consolidate the role of NGS in therapeutic decision-making.
The Genomic testing in metastatic breast cancer They are redefining cancer treatment by providing valuable information about tumor mutations. Although challenges remain in their routine implementation, the data suggest they could become a key tool for precision oncology.
At Zogen, we believe in the importance of innovation in oncology. If you would like to learn more about how genomic testing can help you, contact us and schedule a free consultation.
References:
